Clinical Trial

Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease

Name: Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease — clinical trial record (NCT07756294)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: REVITAA-ALZ

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to find out what effects (good and bad) the study medications (insulin or Empagliflozin) have on adults with mild memory impairment or early Alzheimer's disease who are clinically prescribed an anti-amyloid therapy compared to placebo.

Trial Details

NCT Number	NCT07756294
Lead Sponsor	Wake Forest University Health Sciences
Conditions	Alzheimer Disease
Enrollment	30 participants
Start Date	2026-08
Primary Completion	2028-04 (estimated)
Study Completion	2028-04 (estimated)
Updated on ClinicalTrials.gov	2026-08-10